Hanping Wang

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 27

Top Venues

Thoracic cancer

Hepatology international

Cancer medicine

Peking Union Medical College Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Peking Union Medical College Hospital

China

Associate Chief Physician

Publications

Nan Zhang, Zhaohui Li, Yutao Liu, Xiaohua Shi, Di Shi, Yue Li, Xiaoyan Si, Ziyu Xun, Jing Shao, Haitao Zhao, Hanping Wang
Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics. Hepatology international (2024)
Jing Zhao, Yang Wu, Yuan Yue, Min-Jiang Chen, Yan Xu, Xiangning Liu, Xiaoyan Liu, Xiaoxing Gao, Hanping Wang, Xiao-Yan Si, Wei Zhong, Xiao-Tong Zhang, Li Zhang, Mengzhao Wang
The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer. Thoracic cancer 14 (5) (2023)
Jing Zhao, Yang Wu, Yuan Yue, Min-Jiang Chen, Yan Xu, Xiangning Liu, Xiaoyan Liu, Xiaoxing Gao, Hanping Wang, Xiao-Yan Si, Wei Zhong, Xiao-Tong Zhang, Li Zhang, Mengzhao Wang
The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer. Thoracic cancer 14 (5) (2023)
Kang Miao, Xiao-Tong Zhang, Hanping Wang, Xiao-Yan Si, Li Zhang
Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer. Thoracic cancer (2023)
Jing Zhao, Yang Wu, Yuan Yue, Min-Jiang Chen, Yan Xu, Xiangning Liu, Xiaoyan Liu, Xiaoxing Gao, Hanping Wang, Xiao-Yan Si, Wei Zhong, Xiao-Tong Zhang, Li Zhang, Mengzhao Wang
The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer. Thoracic cancer (2023)
Xiao-Yan Si, Xueqing Zheng, Xinlun Tian, Hanping Wang, Yan Xu, Jing Zhao, Min-Jiang Chen, Wei Zhong, Mengzhao Wang, Li Zhang, Xiao-Tong Zhang
Analysis of cytokines in bronchoalveolar lavage fluid in patients with checkpoint inhibitor pneumonitis and pulmonary infection: A case-control study. Thoracic cancer (2023)
Peng Song, Dongliang Yang, Hanping Wang, Xiaoxia Cui, Xiao-Yan Si, Xiao-Tong Zhang, Li Zhang
Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients. Thoracic cancer 11 (6) (2020)
Peng Song, Xiaotong Zhang, Dongliang Yang, Hanping Wang, Xiao-Yan Si, Li Zhang
Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. Thoracic cancer 11 (5) (2020)
Xiao-Yan Si, Ruili Pan, Shaohua Ma, Lin Li, Li Liang, Ping Zhang, Yuping Chu, Hanping Wang, Mengzhao Wang, Xiao-Tong Zhang, Li Zhang
Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer. Thoracic cancer 12 (3) (2020)
Hanping Wang, Jiaxin Zhou, Xiaoxiao Guo, Yue Li, Lian Duan, Xiao-Yan Si, Li Zhang
Use of glucocorticoids in the management of immunotherapy-related adverse effects. Thoracic cancer 11 (10) (2020)
Xiao-Yan Si, Peng Song, Jun Ni, Mingyi Di, Chunxia He, Li Zhang, Xiaowei Liu, Yue Li, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xu Yang, Mengzhao Wang, Li Zhang
Management of immune checkpoint inhibitor-related adverse events: A review of case reports. Thoracic cancer 11 (3) (2020)
Xiao-Yan Si, Yan You, Xiaotong Zhang, Hanping Wang, Mengzhao Wang, Li Zhang
Histologic transformation of lung cancer during pembrolizumab therapy: A case report. Thoracic cancer 11 (3) (2020)
Peng Song, Dongliang Yang, Hanping Wang, Xiaoxia Cui, Xiao-Yan Si, Xiao-Tong Zhang, Li Zhang
Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients. Thoracic cancer 11 (6) (2020)
Hanping Wang, Yanwei Zhao, Xiaotong Zhang, Xiaoyan Si, Peng Song, Yi Xiao, Xu Yang, Lan Song, Juhong Shi, Haitao Zhao, Li Zhang
Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study. Cancer medicine 10 (1) (2020)
Hanping Wang, Ruili Pan, Xiaotong Zhang, Xiao-Yan Si, Mengzhao Wang, Li Zhang
Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. Thoracic cancer 11 (3) (2020)
Minya Lu, Li Zhang, Yue Li, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xiao-Yan Si, Yingchun Xu, Li Zhang
Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. Thoracic cancer 11 (3) (2020)
Xiao-Wei Liu, Zheng Wang, Chan Zhao, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xiao-Yan Si, Li Zhang, Yue Li, Mengzhao Wang, Meifen Zhang, Li Zhang
Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thoracic cancer 11 (3) (2020)
Xiao-Yan Si, Hanping Wang, Xiao-Tong Zhang, Mengzhao Wang, Yan You, Li Zhang
Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum-pemetrexed: The first report of two cases. Thoracic cancer 11 (8) (2020)
Ke Zheng, Wei Qiu, Hanping Wang, Xiao-Yan Si, Xiaotong Zhang, Li Zhang, Xuemei Li
Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events. Thoracic cancer 11 (6) (2020)
Yue Li, Xiaohui Kang, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xiao-Yan Si, Li Zhang, Xiao-Wei Liu, Jiaming Qian, Li Zhang
Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system. Thoracic cancer 11 (4) (2020)
Junling Zhuang, Jianhua Du, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Wei Qiu, Xiao-Yan Si, Li Zhang, Yue Li, Xiaowei Liu, Hanping Wang, Daobin Zhou, Li Zhang
Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. Thoracic cancer 11 (3) (2020)
Ziwei Liu, Tao Liu, Xiao-Tong Zhang, Xiao-Yan Si, Hanping Wang, Jingjia Zhang, Hui Huang, Xuefeng Sun, Jinglan Wang, Mengzhao Wang, Li Zhang
Opportunistic infections complicating immunotherapy for non-small cell lung cancer. Thoracic cancer 11 (6) (2020)
Lian Duan, Linjie Wang, Hanping Wang, Xiao-Yan Si, Li Zhang, Xiao-Wei Liu, Yue Li, Xiaoxiao Guo, Jiaxin Zhou, Huijuan Zhu, Li Zhang
Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction. Thoracic cancer 11 (4) (2020)
Xiao-Yan Si, Chunxia He, Li Zhang, Xiaowei Liu, Yue Li, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Mengzhao Wang, Li Zhang
Management of immune checkpoint inhibitor-related dermatologic adverse events. Thoracic cancer 11 (2) (2019)
Xiaoxiao Guo, Hanping Wang, Jiaxin Zhou, Yue Li, Lian Duan, Xiao-Yan Si, Li Zhang, Ligang Fang, Li Zhang
Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity. Thoracic cancer 11 (2) (2019)
Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Yue Li, Lian Duan, Xiao-Yan Si, Li Zhang, Xiaowei Liu, Mengzhao Wang, Juhong Shi, Li Zhang
Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. Thoracic cancer 11 (1) (2019)
Jiaxin Zhou, Hanping Wang, Xiaoxiao Guo, Qian Wang, Lian Duan, Xiao-Yan Si, Li Zhang, Xiaowei Liu, Yue Li, Wen Zhang, Li Zhang
Management of immune checkpoint inhibitor-related rheumatic adverse events. Thoracic cancer 11 (1) (2019)

Hanping Wang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hanping Wang